

11-28-01

BOX SEQ A

UTILITY PATENT APPLICATION TRANSMITTAL
(Large Entity)*(Only for new nonprovisional applications under 37 CFR 1.53(b))*Docket No.
DEX-0275

Total Pages in this Submission

TO THE ASSISTANT COMMISSIONER FOR PATENTSBox Patent Application
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

COMPOSITIONS AND METHODS RELATING TO LUNG SPECIFIC GENES AND PROTEINS

and invented by:

Macina et al.

If a **CONTINUATION APPLICATION**, check appropriate box and supply the requisite information:☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____

Enclosed are:

Application Elements

1. ☒ Filing fee as calculated and transmitted as described below
2. ☒ Specification having 145 pages and including the following:
 - a. ☒ Descriptive Title of the Invention
 - b. ☒ Cross References to Related Applications *(if applicable)*
 - c. ☐ Statement Regarding Federally-sponsored Research/Development *(if applicable)*
 - d. ☐ Reference to Microfiche Appendix *(if applicable)*
 - e. ☒ Background of the Invention
 - f. ☒ Brief Summary of the Invention
 - g. ☐ Brief Description of the Drawings *(if drawings filed)*
 - h. ☒ Detailed Description
 - i. ☒ Claim(s) as Classified Below
 - j. ☒ Abstract of the Disclosure

UTILITY PATENT APPLICATION TRANSMITTAL
(Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
DEX-0275

Total Pages in this Submission

Application Elements (Continued)

3. ☐ Drawing(s) *(when necessary as prescribed by 35 USC 113)*
- a. ☐ Formal Number of Sheets _____
- b. ☐ Informal Number of Sheets _____
4. ☒ Oath or Declaration
- a. ☐ Newly executed *(original or copy)* ☒ Unexecuted
- b. ☐ Copy from a prior application (37 CFR 1.63(d)) *(for continuation/divisional application only)*
- c. ☒ With Power of Attorney ☐ Without Power of Attorney
- d. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application,
see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. ☐ Incorporation By Reference *(usable if Box 4b is checked)*
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under
Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby
incorporated by reference therein.
6. ☐ Computer Program in Microfiche *(Appendix)*
7. ☒ Nucleotide and/or Amino Acid Sequence Submission *(if applicable, all must be included)*
- a. ☒ Paper Copy
- b. ☒ Computer Readable Copy *(identical to computer copy)*
- c. ☒ Statement Verifying Identical Paper and Computer Readable Copy

Accompanying Application Parts

8. ☐ Assignment Papers *(cover sheet & document(s))*
9. ☐ 37 CFR 3.73(B) Statement *(when there is an assignee)*
10. ☐ English Translation Document *(if applicable)*
11. ☐ Information Disclosure Statement/PTO-1449 ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Acknowledgment postcard
14. ☒ Certificate of Mailing
- ☐ First Class ☒ Express Mail *(Specify Label No.):* **EV051546974US**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Total Pages in this Submission

15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)

16. ☐ Additional Enclosures (*please identify below*):

--

17. ☐ Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

UTILITY PATENT APPLICATION TRANSMITTAL
(Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
DEX-0275


Total Pages in this Submission

Fee Calculation and Transmittal

CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	19	- 20 =	0	x \$18.00	\$0.00
Indep. Claims	2	- 3 =	0	x \$84.00	\$0.00
Multiple Dependent Claims (check if applicable) <input checked="" type="checkbox"/>					\$280.00
BASIC FEE					\$740.00
OTHER FEE (specify purpose)					\$0.00
TOTAL FILING FEE					\$1,020.00

- ☒ A check in the amount of **\$1,020.00** to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. **50-1619** as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____ as filing fee.
- ☒ Credit any overpayment.
- ☒ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
- ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).


Signature

Kathleen A. Tyrrell, Registration No. 38,350

Dated: November 20, 2001

Licata & Tyrrell P.C.
66 East Main Street
Marlton, N.J. 08053
Tel: 856-810-1515
Fax: 856-810-1454

cc:

DEX-0275


CERTIFICATE OF EXPRESS MAILING

"Express Mail" Label No. EV051546974US

Date of Deposit: November 20, 2001

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R 1.10 on the date indicated above and is addressed to the "BOX SEQUENCE", Assistant Commissioner for Patents, Washington, D.C. 20231.

- 1) Patent Application Transmittal Letter (2 copies);
- 2) Application consisting of 145 pages of Specification, including three (3) pages of Claims and one (1) page of Abstract;
- 3) Return Postcard;
- 4) Unexecuted Declaration and Power of Attorney;
- 5) Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§1.821-1.825;
- 6) Sequence listing;
- 7) Diskette containing computer readable copy of Sequence Listing; and
- 8) Check in the amount of \$1,020.00 for filing fee.


KATHLEEN A. TYRRELL

1004834001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DEX-0275

Inventors: Macina et al.

Serial No.: Not yet assigned

Filing Date: Herewith

Examiner: Not yet assigned

Group Art Unit: Not yet assigned

Title: Compositions and Methods Relating to
Lung Specific Genes and Proteins

"Express Mail" Label No. EV051546974US
Date of Deposit - November 20, 2001

I hereby certify that this paper is being deposited with
the United States Postal Service "Express Mail Post Office
to Addressee" service under 37 CFR 1.10 on the date
indicated above and is addressed to the Assistant Commissioner for
Patents, Washington, D.C. 20231.

By Kathleen A. Tyrell
Typed Name: Kathleen A. Tyrell, Registration No. 38,350

BOX SEQUENCE

Assistant Commissioner for Patents
Washington, DC 20231


Sir:

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 CFR §§ 1.821 THROUGH 1.825

- (XX) I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.
- () I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.

- () I hereby state that the submission filed in accordance with **37 CFR §1.821(h)** does not include new matter or go beyond the disclosure in the international application as filed.
- () I hereby state that the amendments, made in accordance with **37 CFR §1.825(a)**, included in the substitute sheet(s) of the Sequence Listing were made to conform with the current Sequence Listing rules. I hereby state that the substitute sheet(s) of the Sequence Listing does not include new matter.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR §1.825(b)**, is the same as the amended Sequence Listing.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR §1.825(d)**, contains identical data to that originally filed.

Respectfully submitted,


Kathleen A. Tyrrell

Registration No. 38,350

Date: November 20, 2001

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DEX-0275

Applicant: diaDexus, Inc.

Inventors: Macina et al.

Serial No.: Not yet assigned

Filing Date: November 20, 2001

Examiner: Not yet assigned

Group Art Unit: Not yet assigned

Title: Compositions and Methods Relating to
Lung Specific Genes and Proteins

I, Kathleen A. Tyrrell, Registration No. 38,350, certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

On this date: November 23, 2001

Kathleen A. Tyrrell
Kathleen A. Tyrrell, Registration No. 38,350

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Statement to Support Attempted Express Mailing


On November 20, 2001, I, Kathleen A. Tyrrell deposited U.S. Utility Patent Application, Attorney Docket Number DEX-0275 with the United States Post Office in Marlton, NJ with Express Mail Label EV051546974US. The Express Mail package was returned to sender on November 21, 2001.

I hereby declare that the statements made herein of my own knowledge are true and that all statements made on information and

*Receipt date granted
is 11/20/01.
J. Chang
from OPLA*

RECEIVED
NOV 23 2001
U.S. PATENT & TRADEMARK OFFICE

Variable	Mean	SD	Min	Max
Age	38.5	12.5	25	65
Gender	0.5	0.5	0	1
Marital Status	0.5	0.5	0	1
Education	12.5	2.5	9	16
Income	3500	1500	1000	8000
Health Status	0.5	0.5	0	1
Exercise Frequency	2.5	1.5	0	5
Stress Level	4.5	1.5	1	7
Sleep Quality	3.5	1.5	1	6
Dietary Habits	0.5	0.5	0	1
Alcohol Consumption	0.5	0.5	0	1
Smoking Status	0.5	0.5	0	1
Family Size	2.5	1.5	1	5
Work Hours	40	10	20	60
Compliance	0.5	0.5	0	1
Adherence	0.5	0.5	0	1
Engagement	0.5	0.5	0	1
Participation	0.5	0.5	0	1
Attendance	0.5	0.5	0	1
Completion	0.5	0.5	0	1
Success	0.5	0.5	0	1
Outcome	0.5	0.5	0	1
Result	0.5	0.5	0	1
Effectiveness	0.5	0.5	0	1
Efficiency	0.5	0.5	0	1
Productivity	0.5	0.5	0	1
Performance	0.5	0.5	0	1
Quality	0.5	0.5	0	1
Quantity	0.5	0.5	0	1
Value	0.5	0.5	0	1
Importance	0.5	0.5	0	1
Relevance	0.5	0.5	0	1
Significance	0.5	0.5	0	1
Impact	0.5	0.5	0	1
Influence	0.5	0.5	0	1
Power	0.5	0.5	0	1
Authority	0.5	0.5	0	1
Control	0.5	0.5	0	1
Management	0.5	0.5	0	1
Leadership	0.5	0.5	0	1
Direction	0.5	0.5	0	1
Guidance	0.5	0.5	0	1
Instruction	0.5	0.5	0	1
Teaching	0.5	0.5	0	1
Learning	0.5	0.5	0	1
Knowledge	0.5	0.5	0	1
Understanding	0.5	0.5	0	1
Insight	0.5	0.5	0	1
Wisdom	0.5	0.5	0	1
Intelligence	0.5	0.5	0	1
Reasoning	0.5	0.5	0	1
Logic	0.5	0.5	0	1
Analysis	0.5	0.5	0	1
Synthesis	0.5	0.5	0	1
Evaluation	0.5	0.5	0	1
Assessment	0.5	0.5	0	1
Measurement	0.5	0.5	0	1
Quantification	0.5	0.5	0	1
Calculation	0.5	0.5	0	1
Computation	0.5	0.5	0	1
Operation	0.5	0.5	0	1
Process	0.5	0.5	0	1
Method	0.5	0.5	0	1
Technique	0.5	0.5	0	1
Strategy	0.5	0.5	0	1
Tactic	0.5	0.5	0	1
Approach	0.5	0.5	0	1
Style	0.5	0.5	0	1
Form	0.5	0.5	0	1
Shape	0.5	0.5	0	1
Structure	0.5	0.5	0	1
Organization	0.5	0.5	0	1
System	0.5	0.5	0	1
Framework	0.5	0.5	0	1
Model	0.5	0.5	0	1
Paradigm	0.5	0.5	0	1
Theory	0.5	0.5	0	1
Hypothesis	0.5	0.5	0	1
Experiment	0.5	0.5	0	1
Observation	0.5	0.5	0	1
Measurement	0.5	0.5	0	1
Analysis	0.5	0.5	0	1
Synthesis	0.5	0.5	0	1
Evaluation	0.5	0.5	0	1
Assessment	0.5	0.5	0	1
Measurement	0.5	0.5	0	1
Quantification	0.5	0.		


Kathleen A. Tyrrell
Licata & Tyrrell P.C.
66 East Main Street
Marlton, NJ 08053

11-23-2001
Date